#1EXACT Thrive. SCIENCES Earlier Detection Creating a Leader in Blood-Based Multi- Cancer Screening October 27, 2020#2#3Presentation Participants Kevin Conroy Exact Sciences Chairman of the Board & Chief Executive Officer EXACT SCIENCES Thrive. Earlier Detection Jeff Elliott Exact Sciences Chief Financial Officer David Daly Thrive Chief Executive Officer 3#4Establishing Exact Sciences as a Leader in Blood-Based Multi-Cancer Screening M By combining the expertise of Exact Sciences and Thrive, we believe we can bring this powerful technology to patients faster EXACT SCIENCES Thrive. Earlier Detection Transforming the future of cancer diagnostics with a premier R&D team oncotype Accelerating the approval, availability, and adoption of blood- based multi-cancer screening EXACT SCIENCES (₁) cologuard® + Demonstrating Exact Sciences is a research and commercial partner-of-choice Thrive. Earlier Detection CancerSEEK 4#5Screen Fewer People to Detect 1 Cancer with Multi-Cancer Approach Problem #1 Cancer is leading cause of death in people under 85 in U.S. 90% ~9/10 people can survive if it's caught at an early stage EXACT SCIENCES Thrive. Earlier Detection Solution 166 People need to be screened to detect 1 colorectal cancer ~30 People need to be screened to detect 1 type of multiple cancers Sources: Centers for Disease Control and Prevention; U.S. Census Bureau; Imperiale TF et al., N Engl J Med (2014); Karwinski 1990, Burton 1998, Sens 2009, Ahlquist 2017; Assumes -85% sensitivity for a multi-cancer test Market 114M People between ages 50 and 85 in the U.S. who could be screened 5#6#7#8#9#10#11#12#13#14#15